250 related articles for article (PubMed ID: 29473173)
41. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.
Rebulla P; Vaglio S; Beccaria F; Bonfichi M; Carella A; Chiurazzi F; Coluzzi S; Cortelezzi A; Gandini G; Girelli G; Graf M; Isernia P; Marano G; Marconi M; Montemezzi R; Olivero B; Rinaldi M; Salvaneschi L; Scarpato N; Strada P; Milani S; Grazzini G
Transfusion; 2017 May; 57(5):1171-1183. PubMed ID: 28236335
[TBL] [Abstract][Full Text] [Related]
42. Platelet refractoriness and alloimmunization.
Slichter SJ
Leukemia; 1998 Sep; 12 Suppl 1():S51-3. PubMed ID: 9777897
[TBL] [Abstract][Full Text] [Related]
43. Management of the Platelet Refractory Patient.
Forest SK; Hod EA
Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003
[TBL] [Abstract][Full Text] [Related]
44. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
Basire A; Picard C
Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
[TBL] [Abstract][Full Text] [Related]
45. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.
Jackman RP; Deng X; Bolgiano D; Lebedeva M; Heitman JW; Busch MP; Slichter SJ; Norris PJ
Blood; 2013 Apr; 121(16):3261-6; quiz 3299. PubMed ID: 23393051
[TBL] [Abstract][Full Text] [Related]
46. Detection and identification of platelet-associated alloantibodies by a solid-phase modified antigen capture enzyme-linked immunosorbent assay method and its correlation to platelet refractoriness in multiplatelet concentrate-transfused patients.
Jain N; Sarkar S; Philip J
Immunohematology; 2014; 30(3):123-5. PubMed ID: 25695438
[TBL] [Abstract][Full Text] [Related]
47. Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions.
Waterman HR; Kapp LM; Munday A; Odem-Davis K; Zimring JC
Transfusion; 2016 Jan; 56(1):91-100. PubMed ID: 26400622
[TBL] [Abstract][Full Text] [Related]
48. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
[TBL] [Abstract][Full Text] [Related]
49. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients.
Lo SC; Chang JS; Lin SW; Lin DT
Transfusion; 2005 May; 45(5):761-5. PubMed ID: 15847666
[TBL] [Abstract][Full Text] [Related]
50. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization.
Murphy MF; Metcalfe P; Thomas H; Eve J; Ord J; Lister TA; Waters AH
Br J Haematol; 1986 Mar; 62(3):529-34. PubMed ID: 3954967
[TBL] [Abstract][Full Text] [Related]
51. Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice.
Jackman RP; Muench MO; Heitman JW; Inglis HC; Law JP; Marschner S; Goodrich RP; Norris PJ
Transfusion; 2013 Nov; 53(11):2697-709. PubMed ID: 23451715
[TBL] [Abstract][Full Text] [Related]
52. Transfusion of pathogen-reduced platelet components without leukoreduction.
Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
[TBL] [Abstract][Full Text] [Related]
53. Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets.
Karafin MS; Schumacher C; Zhang J; Simpson P; Johnson ST; Pierce KL
Transfusion; 2021 Aug; 61(8):2307-2316. PubMed ID: 34075590
[TBL] [Abstract][Full Text] [Related]
54. D+ platelet transfusions in D- patients: cause for concern?
Bartley AN; Carpenter JB; Berg MP
Immunohematology; 2009; 25(1):5-8. PubMed ID: 19856725
[TBL] [Abstract][Full Text] [Related]
55. Platelet transfusions irradiated with ultraviolet-B light may have a role in reducing recipient alloimmunization.
Tandy NP; Pamphilon DH
Blood Coagul Fibrinolysis; 1991 Apr; 2(2):383-8. PubMed ID: 1893070
[TBL] [Abstract][Full Text] [Related]
56. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
57. [Refractory effect and alloimmunization after transfusion of thrombocytes].
Volkova RI; Agranenko VA
Gematol Transfuziol; 1992 Feb; 37(2):16-21. PubMed ID: 1426903
[TBL] [Abstract][Full Text] [Related]
58. Alloimmunization as a problem for platelet transfusion.
Bonacossa IA
Transfus Med Rev; 1990 Apr; 4(2):144-8. PubMed ID: 2134622
[No Abstract] [Full Text] [Related]
59. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
60. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
